与Atezolizumab相关的免疫相关的不良事件:来自现实世界药监数据的见解
1Department of Medicine, University of British Columbia, 317-2194 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada.
Antibodies (Basel, Switzerland)
|July 25, 2024
概括
作为一种免疫检查点抑制剂的阿特佐利祖马布 (Atezolizumab) 可以引起广泛的免疫相关不良事件,影响多个器官系统. 这项研究强调了癌症患者的显著风险,包括脑炎和心肌炎.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药物监督 药物监督 药物监督
背景情况:
- 免疫瘤学,特别是以抗体为基础的免疫检查点抑制剂,如阿特佐利祖马布,已经改变了癌症治疗.
- 检查点封锁导致T细胞活动增加可能导致与免疫相关的不良事件 (irAEs),其全谱尚未完全理解.
研究的目的:
- 调查与阿特佐利祖马布使用相关的irAEs的频谱和相对风险.
- 为了确定特定的器官系统和条件最常受到阿特佐利祖马布诱导的irAEs的影响.
主要方法:
- 使用美国食品和药物管理局不良事件报告系统 (FAERS) 数据库.
- 分析报告的不良事件,以识别与阿特佐利祖马布相关的irAEs的信号.
主要成果:
- 在多个器官系统 (心血管,呼吸道,肝脏,脏,神经系统等) 确定了49种不同的irAEs. ) 的情况.
- 对免疫媒介脑炎 (RR=93.443),自身免疫性心肌炎 (RR=56.641),自身免疫性肝炎 (RR=49.062),自身免疫性炎 (RR=40.947) 和自身免疫性关节炎 (RR=39.382) 观察到的最高相对风险 (RR) 信号.
结论:
- 阿特佐利祖马布治疗与广泛的irrAEs相关,导致癌症患者的显著发病率和死亡率.
- 临床医生应该意识到这些潜在的不良事件,同时也考虑潜在的生存益处的新兴证据.
- 需要进一步的研究才能充分理解这些IRAE的影响及其与治疗结果的关联.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.3K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
相关概念视频
01:19Pharmacovigilance
810
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
810
01:27Allergic Drug Reactions
828
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
828